Phase I, open-label, dose-escalation, safety and PK study of AZD4877

Study identifier:D2782C00006

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients with Advanced Solid Malignancies including Lymphoma

Medical condition

Lymphoma

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD4877

Sex

All

Actual Enrollment

44

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Apr 2007
Primary Completion Date: -
Study Completion Date: 01 Dec 2008

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria